Kidney Disease, Chronic

Nephrology
3
Pipeline Programs
3
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
6 programs
2
1
BI 690517Phase 31 trial
BI 690517Phase 21 trial
BI 764198Phase 21 trial
JARDIANCE®N/A1 trial
JARDIANCE®N/A1 trial
+1 more programs
Active Trials
NCT06527846Active Not Recruiting1,027Est. May 2027
NCT06287073Completed299Est. Apr 2025
NCT06223750Enrolling By Invitation3,356Est. Apr 2029
+3 more trials
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Methoxy polyethylene glycol-epoetin betaN/A1 trial
Active Trials
NCT02547454Completed393Est. Nov 2014
Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
Pea hull fiberN/A1 trial
Active Trials
NCT03354364CompletedEst. Aug 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Boehringer IngelheimBI 690517
Boehringer IngelheimBI 764198
Boehringer IngelheimBI 690517
Boehringer Ingelheimpopulation-based screening for chronic kidney disease
Boehringer IngelheimJARDIANCE®
Boehringer IngelheimJARDIANCE®
Pulse BiosciencesPea hull fiber
RocheMethoxy polyethylene glycol-epoetin beta

Clinical Trials (8)

Total enrollment: 16,856 patients across 8 trials

NCT06531824Boehringer IngelheimBI 690517

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Start: Aug 2024Est. completion: Aug 202811,000 patients
Phase 3Recruiting
NCT05213624Boehringer IngelheimBI 764198

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

Start: May 2022Est. completion: Jan 202567 patients
Phase 2Completed
NCT05182840Boehringer IngelheimBI 690517

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Start: Jan 2022Est. completion: Jul 2023714 patients
Phase 2Completed
NCT06223750Boehringer Ingelheimpopulation-based screening for chronic kidney disease

Virtual Kidney Check and Follow-up

Start: Nov 2024Est. completion: Apr 20293,356 patients
N/AEnrolling By Invitation
NCT06527846Boehringer IngelheimJARDIANCE®

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Start: Oct 2024Est. completion: May 20271,027 patients
N/AActive Not Recruiting
NCT06287073Boehringer IngelheimJARDIANCE®

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

Start: Mar 2024Est. completion: Apr 2025299 patients
N/ACompleted
NCT03354364Pulse BiosciencesPea hull fiber

Efficacy of Pea Hull Fiber in Chronic Disease

Start: Dec 2017Est. completion: Aug 2019
N/ACompleted
NCT02547454RocheMethoxy polyethylene glycol-epoetin beta

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Start: Dec 2008Est. completion: Nov 2014393 patients
N/ACompleted

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 16,856 patients
3 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)